GLI2-Mediated Melanoma Invasion and Metastasis


Manuscript received April 11, 2009; revised May 17, 2010; accepted June 1, 2010.

Correspondence to: Alain Mauviel, PhD, Curie Institute, INSERM U1021/CNRS UMR3347, University Center, Bldg 110, Rm 216, 91405 Orsay Cedex, France (e-mail: alain.mauviel@curie.fr).

Background The transforming growth factor-β (TGF-β) pathway, which has both tumor suppressor and pro-oncogenic activities, is often constitutively active in melanoma and is a marker of poor prognosis. Recently, we identified GLI2, a mediator of the hedgehog pathway, as a transcriptional target of TGF-β signaling.

Methods We used real-time reverse transcription–polymerase chain reaction (RT-PCR) and western blotting to determine GLI2 expression in human melanoma cell lines and subsequently classified them as GLI2high or as GLI2low according to their relative GLI2 mRNA and protein expression levels. GLI2 expression was reduced in a GLI2high cell line with lentiviral expression of short hairpin RNA targeting GLI2. We assessed the role of GLI2 in melanoma cell invasiveness in Matrigel assays. We measured secretion of matrix metalloproteinase (MMP)-2 and MMP-9 by gelatin zymography and expression of E-cadherin by western blotting and RT-PCR. The role of GLI2 in development of bone metastases was determined following intracardiac injection of melanoma cells in immunocompromised mice (n = 5–13). Human melanoma samples (n = 79) at various stages of disease progression were analyzed for GLI2 and E-cadherin expression by immunohistochemistry, in situ hybridization, or RT-PCR. All statistical tests were two-sided.

Results Among melanoma cell lines, increased GLI2 expression was associated with loss of E-cadherin expression and with increased capacity to invade Matrigel and to form bone metastases in mice (mean osteolytic tumor area: GLI2high vs GLI2low, 2.81 vs 0.93 mm², difference = 1.88 mm², 95% confidence interval [CI] = 1.16 to 2.60, P < .001). Reduction of GLI2 expression in melanoma cells that had expressed high levels of GLI2 substantially inhibited both basal and TGF-β-induced cell migration, invasion (mean number of Matrigel invading cells: shGLI2 vs shCtrl [control], 52.6 vs 100, difference = 47.4, 95% CI = 37.0 to 57.8, P = .024; for shGLI2 + TGF-β vs shCtrl + TGF-β, 31.0 vs 161.9, difference = −130.9, 95% CI = −96.2 to −165.5, P = .002), and MMP secretion in vitro and the development of experimental bone metastases in mice. Within human melanoma lesions, GLI2 expression was heterogeneous, associated with tumor regions in which E-cadherin was lost and increased in the most aggressive tumors.

Conclusion GLI2 was directly involved in driving melanoma invasion and metastasis in this preclinical study.


Melanoma represents approximately 4% of human skin cancers, yet accounts for approximately 80% of deaths from cutaneous neoplasms (1). Although progress has been made in understanding the genetics of the molecular events underlying melanoma oncogenesis (2–4), the clinical challenge remains enormous. A genetic hallmark of melanoma is the presence of activating mutations in the oncogenes BRAF and NRAS, which are present in 70% and 15% of melanomas, respectively, and lead to constitutive activation of mitogen-activated protein kinase pathway signaling (3,5). However, molecules that inhibit mitogen-activated protein kinase pathway–associated kinases, like BRAF and MEK, have shown only limited efficacy in the treatment of metastatic melanoma (6). Thus, a deeper understanding of the cross talk between signaling networks and the complexity of melanoma progression should lead to more effective therapy.

Hedgehog (HH) signaling is controlled at the cell surface by two transmembrane proteins, the tumor suppressor Patched-1 (PTCH1), which acts as a HH receptor, and the oncoprotein Smoothened (SMO). In the absence of HH, PTCH1 maintains SMO in an inactive state. In the presence of any of the three HH ligands (Sonic, Indian, or Desert HH), inhibition of SMO by PTCH1 is alleviated and a signal is transduced that leads to the nuclear translocation and activation of GLI family transcription factors (7,8). GLIs are often overexpressed in cancers and contribute to the progression of a variety of neoplasms via regulation of cell cycle progression and apoptosis (9,10). One recent study (11)
suggested that the HH pathway may play a role in melanoma progression based on pharmacological inhibition of HH signaling in genetic mouse models of melanoma.

Transforming growth factor-β (TGF-β) is a potent inhibitor of normal epithelial cell proliferation. However, it is secreted in abundance by tumor cells and exerts pro-oncogenic activities in later stages of tumor progression (12–14). Members of the TGF-β superfamily signal via heteromeric serine/threonine kinase transmembrane receptor complexes that, on ligand binding, phosphorylate SMAD family proteins that mediate signaling from the cell membrane to the nucleus (15,16). In vivo, malignant melanomas secrete high amounts of TGF-β, and increased circulating plasma concentrations of TGF-β are associated with the advancing stage of the tumor (17,18). TGF-β also exerts paracrine effects on angiogenesis and immune surveillance, thereby promoting tumor growth and survival (19). Autocrine TGF-β signaling and SMAD-dependent transcriptional responses directly exacerbate melanoma cell tumorigenicity and metastasis (20–22).

Recently, we determined that the gene for GLI2, which is the most transcriptionally active of the GLI proteins, was directly induced by TGF-β and SMAD signaling (23). Furthermore, the GLI2 protein mediates the induction of GLI1 expression in response to TGF-β, independent of HH signaling (23).

In this report, we have analyzed the specific role played by GLI2 in human melanoma. We used a combination of in vitro and in vivo experimental approaches to determine whether GLI2 expression is associated with melanoma cell invasion, matrix metalloproteinase (MMP) secretion, expression of E-cadherin, and metastasis to bone. Reduction of GLI2 expression with specific short hairpin RNA (shRNA) vectors was used to directly address the functionality of GLI2 in these experimental settings. To gain insight into the pathophysiological relevance of our findings in melanoma, expression of GLI2, together with that of E-cadherin, was determined in human melanoma tumors.

Materials and Methods

Cell Cultures and Reagents

Human melanoma cell lines that were derived from tumor biopsies from patients with either primary (WM793, 888mel, Dauv1, and WM983A) or metastatic (WM983B [same patient as WM983A], WM852, 501mel, FO-1, and SK28) melanoma lesions were grown in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS) and antibiotics. 1205Lu melanoma cells in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS) and antibiotics. 1205Lu melanoma cells were obtained from the American Type Culture Collection (Manassas, VA). A GLI2-specific reporter plasmid (GLI-BS)-luc were gifts from H. Sasaki (Osaka University) and have been described previously (24). pRL-TK was from Promega (Madison, WI). TGF-β1 was purchased from R&D Systems, Inc (Minneapolis, MN). Expression vectors carrying dominant-negative and constitutively active versions of mouse GLI2 and the GLI-specific reporter plasmid (GLI-BS)-luc were gifts from H. Sasaki (Osaka University) and have been described previously (28,29). pRL-TK was from Promega (Madison, WI).

RNA Extraction and Gene Expression Analysis

Total RNA was isolated from cell cultures using an RNeasy kit (Qiagen GmbH, Hilden, Germany). Genomic DNA contamination was eliminated by DNase I treatment. One microgram of RNA was reverse transcribed using the Thermoscript kit (Invitrogen). The resulting cDNAs were then processed for either semi quantitative or real-time RT-PCR using either ethidium bromide staining of electrophoretically separated amplimers or SYBR Green technology (Applied Biosystems, Foster City, CA). In the latter case, reactions were carried out in a 7300 Real-Time PCR System (Applied Biosystems) for 40 cycles (95°C for

CONTEXT AND CAVEATS

Prior knowledge
The gene for hedgehog pathway component GLI2 was reported to be induced by transforming growth factor-β signaling, which promotes melanoma tumorigenicity, but a role for GLI2 in melanoma invasion and metastasis had not been tested.

Study design
Melanoma cell lines that expressed high or low levels of GLI2 (GLI2high vs GLI2low) or that expressed shRNA to GLI2 or constitutively active GLI2 were compared in Matrigel invasion assays and in assays of bone metastasis after intracardiac injection of immunocompromised mice. Levels of GLI2 expression were also examined in staged human melanoma tissue specimens.

Contribution
Elevated GLI2 expression was associated with greater invasiveness of melanoma cells in vitro and with increased number and size of osteolytic metastases in mice. Overall, GLI2 expression was increased in more aggressive tumors.

Implications
GLI2 may play a role in melanoma invasion and metastasis.

Limitations
Most experiments were done with melanoma cell lines in an in vitro invasion assay or in an immunocompromised mouse model of bone metastasis, whereas in immunocompetent humans, melanoma cells would most likely metastasize to lung, soft tissue, and brain. Evaluation of GLI2 in clinical specimens was limited by the number of specimens available and the lack of a good antibody for immunohistochemistry.

From the Editors

15 seconds and 60°C for 1 minute) after an initial 10-minute incubation at 95°C. Data were analyzed using Applied Biosystems Sequence Detection Software (version 1.2.1) and normalized to cyclophilin A (PPIA) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Five independent experiments were performed to validate gene expression data in each cell line. Primer sequences for multiplex semiquantitative RT-PCR and for realtime RT-PCR are provided in Supplementary Tables 1 and 2, respectively (available online).

**Western Blotting**

Protein extraction and western blotting were performed in three independent experiments as previously described (22). Goat polyclonal anti-GLI2 (sc-20291, 1:200 dilution); rabbit polyclonal anti-E-cadherin (sc-7870, 1:500 dilution); and secondary donkey anti-mouse, anti-goat, and anti-rabbit horseradish peroxidase-conjugated antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Mouse monoclonal anti-GAPDH (ab8245, 1:5000 dilution) was from Abcam (Cambridge, MA), and anti-ß-actin (A4700, 1:1000 dilution) was from Sigma-Aldrich.

**Stable GLI2 Silencing in 1205Lu Human Melanoma Cells**

Subconfluent 1205Lu cells were infected with lentiviruses that expressed either control, nontargeting, shRNA (shCtrl; Sigma-Aldrich SHC002V) or shRNA targeting GLI2 (Sigma-Aldrich SHVRS clone ID TRCN0000033329 and TRCN0000033330) at a multiplicity of 8 plaque-forming units per cell in presence of 8 µg/mL hexadimethrine bromide. Stably transduced cell populations were selected with puromycin (2 µg/mL). Efficient and stable reduction of GLI2 mRNA expression over time was verified by real-time RT-PCR after each passage and before experiments.

**Stable Transfections**

Truncated forms of mouse GLI2 that expressed GLI2 proteins with deletions of amino acids 1184–1544 (GLI2-ΔC2) or 1–279 (GLI2-ΔN2) were used as dominant-negative and constitutively active GLI2 mutants, respectively (29). SK28 and 1205Lu melanoma cells were transfected at approximately 70%–80% confluence with 10 µg of either the empty expression vector (ctrl) or the same vector carrying constitutively active GLI2-ΔN2 or dominant-negative GLI2-ΔC2 (29) per 100-mm-diameter culture dish using the polycationic compound Fugene (Roche Diagnostics, Indianapolis, IN) in fresh medium containing 1% FCS. Effort and stable reduction of GLI2 mRNA expression over time was verified by real-time RT-PCR after each passage and before experiments.

**Gelatin Zymography**

The presence of MMP-2 and MMP-9 in serum-free conditioned media was analyzed by zymography in 10% sodium dodecyl sulfate–polyacrylamide gels containing 1 mg/mL gelatin (Sigma-Aldrich). After removal of sodium dodecyl sulfate with Triton X-100, neutral protease activity was revealed by incubation of the gels for 48 hours at 37°C in 0.1 M Tris–HCl buffer (pH 7.4) containing 10 mM CaCl₂, followed by staining in 0.5% Coomassie blue in an aqueous solution containing 30% isopropanol and 10% acetic acid and destaining in 30% isopropanol and 10% acetic acid (30). Three independent experiments were performed.

**Wound Closure Assays**

For scratch wound assays, freshly confluent monolayers of shCtrl and shGLI2-transfected 1205Lu cells were wounded by manually scraping off cells with a sterile pipette tip. Following wounding of the monolayers, wound sizes were verified to ensure that they were all the same width (approximately 0.8 mm). The cell culture medium was then replaced with fresh RPMI containing 4 µg/mL mitomycin C (Sigma-Aldrich), and wound closure was monitored over a 48-hour period with a phase contrast microscope at ×200 magnification. Experiments were repeated three times.

**Experimental Bone Metastasis in Mice**

The protocols for bone metastasis experiments in athymic female nude mice were approved by the Institutional Animal Care and Use Committee at the University of Virginia in Charlottesville and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Harlan-Sprague-Dawley athymic nude-Foxn Nu mice (nu/nu, n = 72) were purchased from Harlan (Indianapolis, IN). In brief, following anesthesia of each mouse by intraperitoneal injection with a mixture of 30% ketamine and 20% xylazine in 0.9% NaCl (7 mg/100 g body weight), the left cardiac ventricle was punctured percutaneously using a 26-gauge needle attached to a 1-mL syringe containing suspended tumor luciferase assay kit according to the manufacturer’s protocol (Promega). In general, three independent experiments were performed using triplicate samples, but the number varied among experiments and is detailed in the corresponding figure legends.

**Matrigel Invasion Assays**

Tissue culture Transwell inserts (8 µm pore size; Falcon, Franklin Lakes, NJ) were coated for 3 hours with 10 µg of growth factor–reduced Matrigel (Biocoat; BD Biosciences, San Jose, CA) in 100 µL of PBS at 37°C. After air-drying the chambers for 16 hours, the Matrigel barrier was reconstituted with 100 µL Dulbecco’s minimal essential medium for 24 hours at 37°C. The chambers were then placed into 24-well dishes containing 750 µL of RPMI medium supplemented with 0.1% FCS. 5 x 10⁴ melanoma cells (1205Lu, WM793, WM852, Dauv1, WM983A, WM983B, SK28, 501mel, and 888mel) were added to the upper well of each chamber in 500 µL of serum-free RPMI medium. After a 24-hour incubation period, the number of invading cells was counted by bright field microscopy at ×200 in six random fields. Additional details of the procedure may be found in Javlela et al. (21). Experiments were performed four times using duplicate samples.
cells. Visualization of bright red blood entering the hub of the needle in a pulsatile fashion indicated a correct position in the left cardiac ventricle. Tumor cells (10^6 in 0.1 mL of PBS) were inoculated slowly over 1 minute. Mice were followed by radiography for the development of bone lesions throughout the experiments. Images were saved, and lesion areas were measured and analyzed using MetaMorph software (Molecular Devices, Downingtown, PA). Briefly, the images were calibrated, and the edges of the translucent area that represents area of bone loss were identified and traced with a computer mouse pointer, and the area was measured in squared millimeter units. Details of the experimental procedures may be found in several past publications (22,31–33). Mice bearing human tumor xenografts were carefully monitored for established signs of distress and discomfort including development of cachexia (as defined by loss of 20% of original body weight) and inability of the mouse to move and reach for the food source and were humanely killed when these were confirmed.

**Immunohistochemistry and In Situ Hybridization on Human Tissues**

Formaldehyde-fixed and paraffin-embedded melanomas (n = 20) from adult patients were obtained from the pathology archives of the Radboud University Nijmegen Medical Centre. All specimens were reevaluated by an expert pathologist. Tissues were obtained according to local ethical guidelines and approved by the local regulatory committee. Paraffin-embedded 4-µm sections were dewaxed and rehydrated through graded alcohol baths. After an antigen retrieval step with Tris-buffered EDTA (1 mM, pH 9.0, for 10 minutes at 95°C), tissue paraffin sections were preincubated with 20% normal horse serum and subsequently incubated with a mouse monoclonal antibody directed against E-cadherin (Neomarkers, clone SPM471, 1:300 dilution) in PBS containing 1% bovine serum albumin overnight at 4°C. As a secondary reagent, a horseradish peroxidase–conjugated goat anti-mouse antibody from the Powervision system (Immunovision Labs, Brisbane, CA) was used at a 1:2 dilution. Diaminobenzidine served as a chromogen. Counterstaining was performed with hematoxylin.

For in situ hybridization, a 340-bp human GLI2 cDNA fragment was generated by RT-PCR. Briefly, total RNA isolated from 1205Lu melanoma cells was isolated with Trizol (Invitrogen) according to the manufacturer’s protocol, and 1 µg was reverse transcribed for subsequent PCR analysis. GLI2 expression was highly variable: Dauv1, WM852, 1205Lu, and WM793 cells expressed high levels of GLI2 mRNA (Figure 1, A, lanes 2, 6, 9, and 10), whereas in 888mel, SK28, WM983B, and 501mel, and FO-1 cells (lanes 3–5), GLI2 mRNA was barely detectable under the same PCR conditions. SK28, WM983B, and WM983A cell lines (lanes 1, 7, and 8) expressed GLI2 mRNA at high levels, and expression of GLI1, another known GLI2 target (36), was increased in all cell lines that expressed high levels of GLI2 mRNA. GLI2 mRNA at high levels, and expression of GLI1, another known GLI2 target (36), was increased in all cell lines that expressed high levels of GLI2 mRNA except Dauv1 cells. Sonic hedgehog mRNA was undetectable in all melanoma cell lines except 501mel, whereas it was readily detected under the same PCR conditions in human pancreatic adenocarcinoma cell lines (data not shown). Expression of SMO and GLI3, at the mRNA level, was similar among all melanoma cell lines. Quantitative RT-PCR confirmed the results of multiplex semiquantitative RT-PCR and determined that GLI2 mRNA expression in Dauv1,

**Tissue Harvesting and Total RNA Isolation**

Tumor samples were obtained through the Tissue Retrieval Service of the Cancer Institute of New Jersey, following ethical committee guidelines of the University of Medicine and Dentistry of New Jersey (UMDNJ)–Robert Wood Johnson Medical School Institutional Review Board (n = 42), and from the tissue bank at Hôpital Ambroise Paré under the supervision of the local ethical committee (Comité de Protection des Personnes IDF8) (n = 17). Tissue samples were collected such that no patient-identifiable information was included with the specimens, but tumor location and stage were recorded. Details have been described previously (35). Tumor specimens from both locations had been flash frozen in liquid nitrogen within 5 minutes of resection and stored until RNA extraction. Total RNA was isolated from samples using a standard, spin column–based kit (RNeasy; Qiagen) and reverse transcribed for subsequent PCR analysis.

**Statistical Analyses**

For Matrigel invasion and gene expression in human tumor samples, we used the t-test to calculate 95% confidence intervals (CIs) on differences between means and the Mann–Whitney test to obtain the P value. For data related to experimental bone metastasis in mice, differences in osteolytic lesion areas between groups were determined by two-way analysis of variance with Bonferroni posttests (GraphPad Prism). All statistical tests were two-sided. All results were expressed as means with 95% confidence intervals, and P < .05 was considered to be statistically significant.

**Results**

**GLI2 Expression and Invasive Potential of Human Melanoma Cell Lines**

We first determined the expression of the main HH pathway components in a panel of 10 human melanoma cell lines by semiquantitative RT-PCR. GLI2 expression was highly variable: Dauv1, WM852, 1205Lu, and WM793 cells expressed high levels of GLI2 mRNA (Figure 1, A, lanes 2, 6, 9, and 10), whereas in 888mel, 501mel, and FO-1 cells (lanes 3–5), GLI2 mRNA was barely detectable under the same PCR conditions. SK28, WM983B, and WM983A cell lines (lanes 1, 7, and 8) expressed GLI2 mRNA at intermediate levels, similar to those found in normal human melanocytes (lane 11). Expression of PTCH1, which was previously identified as a GLI2 transcriptional target (36), was increased in all but one cell line, WM852, among those cell lines that expressed GLI2 mRNA at high levels, and expression of GLI1, another known GLI2 target (37), was also elevated in all cell lines that expressed high levels of GLI2 mRNA except Dauv1 cells. Sonic hedgehog mRNA was undetectable in all melanoma cell lines except 501mel, whereas it was readily detected under the same PCR conditions in human pancreatic adenocarcinoma cell lines (data not shown). Expression of SMO and GLI3, at the mRNA level, was similar among all melanoma cell lines. Quantitative RT-PCR confirmed the results of multiplex semiquantitative RT-PCR and determined that GLI2 mRNA expression in Dauv1,
Figure 1. Expression of Sonic Hedgehog (SHH) pathway components in a panel of human melanoma cell lines and relationship between GLI2 levels and Matrigel invasion. Cell lines expressing high levels of GLI2 (GLI2high) are shown in red, and cell lines expressing low levels of GLI2 (GLI2low) are shown in blue. A) Semiquantitative multiplex reverse transcription–polymerase chain reaction (RT-PCR). GLI1, GLI3, GLI2, SHH, Smoothened (SMO), and Patched1 (PTCH1) mRNA expression was measured in 10 human melanoma cell lines (lanes 1–10) and normal human epidermal melanocytes (NHEM, lane 11) in culture. Expression of the glyceroldehyde-3-phosphate dehydrogenase gene, GAPDH, was examined as a control in the same RT-PCR reaction as each gene of interest. B) Western blot analysis. GLI2 protein levels were determined in various melanoma cell lines using 100 µg protein per lane. Determination of GAPDH levels served as a loading control. C) Matrigel invasion assay. Melanoma cells (5 × 10⁴) were added to the upper well of each Matrigel invasion chamber in serum-free RPMI medium. Gelatin zymography identified markedly higher levels of MMP-2 secreted by the GLI2high cell lines (1205Lu, WM852, and, to a lesser extent, Dauv1), as compared with the GLI2low cell lines (WM983A, WM983B, SK28, 501mel, and 888mel; data not shown). MMP-2 is an extracellular matrix–degrading enzyme that is often used by cancer cells to invade basement membranes and progress toward a metastatic state (38).

Modulation of the Invasive Potential of Melanoma Cells by Altering GLI2 Function

To ascertain a causal relationship between GLI2 expression levels and melanoma cell aggressiveness, we transduced 1205Lu cells with a lentiviral vector carrying GLI2-specific shRNA to establish stable reduction of GLI2 protein expression or with a vector that expressed a control shRNA. GLI2 silencing resulted in approximately 85% reduction in GLI2 protein expression (Figure 2, A), a marked (approximately 75%) reduction in MMP-2 secretion (Figure 2, B) and a 50%–70% inhibition of the invasive capacity of 1205Lu cells in Matrigel (mean invasiveness for shGLI2 vs shCtrl, 52.6 vs 100 cells per six random microscopic fields, difference = 47.4, 95% CI = 37.0 to 57.8, P = .024) (Figure 2, C). Notably, reduction of GLI2 protein levels also abrogated the stimulatory effect of TGF-β on MMP-2 and MMP-9 secretion (Figure 2, B) and on Matrigel invasion (in the presence of TGF-β, mean invasiveness for shGLI2 vs shCtrl, 31.0 cells per six random microscopic fields vs 161.9 cells per six fields, difference = −130.9, 95% CI = 96.2 to 165.5, P = .002) (Figure 2, C). Furthermore, reduction of GLI2 protein levels strongly impaired cell motility, as visualized by the delayed closure of the gaps generated in cultured 1205Lu cell monolayers in the scratch wound assay (Figure 2, D), and by 85% inhibition of 1205Lu cell migration in a Transwell migration assay (data not shown). Similar results were obtained when GLI2-dependent transcription was altered in 1205Lu melanoma cells by means of stable expression of a dominant-negative mutant form of GLI2, GLI2-AC2 (29) (data not shown).
Inversely, stable expression of a constitutively active form of GLI2, GLI2-ΔN2, in the GLI2low SK28 melanoma cell line effectively enhanced GLI-dependent transcription (Figure 2, E) and dramatically increased the capacity of SK28 cells to invade Matrigel (mean invasiveness for GLI2-ΔN2–expressing SK28 cells vs control SK28 cells, 28.5 vs eight cells per six random microscopic fields, difference = −20.5, 95% CI = −36.4 to −4.60, P = .057) (Figure 2, F). Taken together, these experiments establish a direct role for GLI2 in driving the invasive potential of melanoma cells.

Figure 2. A role for GLI2 in melanoma cell migration and invasion. A) GLI2 silencing. GLI2 protein expression was silenced in 1205Lu human melanoma cells by infection with lentiviral particles carrying a short hairpin RNA (shRNA) against GLI2 (shGLI2). A nontargeting shRNA (shCtrl) was used as control. Relative GLI2 protein levels were measured by western blotting, and blots were reprobed with antibody to β-actin as an internal control. B) Matrix metalloproteinase (MMP)-2 and MMP-9 secretion by 1205Lu cells expressing shGLI2 or control shRNAs. Cells were cultivated 72 hours in serum-free medium in the absence or presence of 10 ng/mL transforming growth factor-β (TGF-β), conditioned medium was collected and subjected to electrophoresis, and MMP activity was visualized by gelatin zymography. The experiment was repeated three times, and a representative experiment is shown. C) Matrigel invasion assay. After stable transfection with control shRNA (shCtrl) or shGLI2, 1205Lu melanoma cells were incubated in the absence or presence of 10 ng/mL TGF-β. Then, 5 × 10⁶ cells were added to the upper well of each Matrigel invasion chamber in serum-free RPMI medium with or without 10 ng/mL TGF-β. The number of invading cells was counted 24 hours later using bright field microscopy at ×200 in six random fields. Results are expressed as the mean of three independent experiments, each performed in duplicate. D) Wound closure assays. Confluent monolayers of shCtrl and shGLI2 1205Lu melanoma cells were wounded by a scratch with a pipette tip. Culture medium was replaced with fresh medium containing mitomycin (4 µg/mL) to prevent cell proliferation. Wound closure was monitored by phase contrast microscopy. A representative photograph at ×200 magnification for each condition is shown. Photos were taken immediately (0 hours) or 48 hours after wounding. Experiments were repeated three times with similar results. E) GLI2-dependent transcription. SK28 human melanoma cells were stably transfected with either an expression vector carrying the gene for the constitutively active mutant, GLI2-ΔN2, or the empty vector (ctrl). GLI2-dependent transcription was measured by transient transfection of these cells with the GLI reporter construct (GLI-BS)₄-luc and measurement of the activity of the luciferase reporter. Results, expressed as relative luciferase activity, are the mean of two independent experiments, each performed with duplicate samples. F) Matrigel invasion assays of ctrl- and GLI2-ΔN2–transfected SK28 melanoma cells. The cells described in (E) were treated as described in (C). The number of invading cells was counted 24 hours later using bright field microscopy at ×200 in six random fields. Results are expressed as the mean of three independent experiments, each performed in duplicate. Statistical analysis was performed using the Mann–Whitney test. Error bars are 95% confidence intervals. All statistical tests were two-sided.
Figure 3. GLI2 expression in melanoma cells and incidence of bone metastasis in mice. A) Incidence of bone metastasis. Mice (n = 5–8) were inoculated by injection of the left cardiac ventricle with GLI2high melanoma cells (1205Lu and WM852) or GLI2low cell lines (SK28, 888Mel, and 501Mel). The development of bone metastases is shown by representative x-ray images of the hind limbs of the mice at 4 weeks after intracardiac inoculation. Arrows indicate osteolytic lesions. For each cell type, the percent incidence of bone metastases is shown. B) Mouse survival. Kaplan–Meier curves are shown for mice inoculated with various melanoma cell lines. Cells expressing high amounts of GLI2 (GLI2high) are shown in red, and cells expressing low amounts (GLI2low) are shown in blue. Blue squares: SK28, blue diamonds: 888Mel, blue triangles: 501Mel, red circles: WM852, red triangles: 1205Lu. The Mann–Whitney test was used to assess the difference in survival between groups. Mice inoculated with GLI2low cells survived longer than those with GLI2 cells (mean survival for all GLI2high cell lines [1205Lu + WM852] = 29.7 days, mean survival for all GLI2low cell lines [888Mel + SK28 + 501Mel] = 39.1 days, difference = 9.4 days, 95% confidence interval [CI] = 5.22 to 13.64, P < .001). The number of mice at risk (for those inoculated with 1205Lu or 888Mel melanoma cells) at days 0 and 30 and the 95% confidence interval for survival at 4 weeks are also shown. C) Osteolytic lesion area following intracardiac inoculation of melanoma cells in mice. Blue squares: SK28, blue diamonds: 888Mel, blue triangles: 501Mel, red circles: WM852, red triangles: 1205Lu. Error bars are 95% confidence intervals. Two-way analysis of variance with Bonferroni posttests adjusted for multiple comparisons: 1205 vs SK28: P < .001; 1205Lu vs 888Mel: P < .001; 1205Lu vs 501Mel: P < .01; 1205Lu vs WM852: not significantly different (n.s.); WM852 vs SK28: P < .001; WM852 vs 888Mel: P < .001; 501Mel vs 888Mel: P < .01; SK28 vs 888Mel: n.s., SK28 vs 501Mel: n.s., 888Mel vs 501Mel: n.s. All GLI2high (1205Lu + WM852) vs all GLI2low (SK28 + 888Mel + 501Mel): P < .001. Error bars reflect 95% confidence intervals. D) Effect of GLI2 silencing on the incidence of bone metastasis after intracardiac inoculation. Representative x-ray images of the hind limbs of mice (n = 12–13) bearing bone metastases 4 weeks after the inoculation of 1205Lu melanoma cells expressing either of two short hairpin RNAs (shRNAs) to GLI2 (shGLI2-1 and shGLI2-2) vs control shRNA (shCtrl) are shown. Arrows indicate osteolytic lesions, and for each cell type, the percent incidence of bone metastases is shown. E) Incidence of osteolytic metastases in mice (n = 12–13) following intracardiac injection of 1205Lu cells that expressed GLI2 or control shRNA. The area occupied by osteolytic lesions on radiographs was measured by computerized image analysis of radiographs of the forelimbs and hind limbs at 4 weeks postinoculation. The size of metastases from mice with the following is shown: black squares, cells with control shRNA (shCtrl); black triangles, shGLI2-1; open circles, shGLI2-2 (shCtrl vs shGLI2-1: P < .05; shCtrl vs shGLI2-2: P < .001). Error bars reflect 95% confidence intervals.
To determine whether there is a causal relationship between GLI2 expression and metastasis, two distinct populations of 1205Lu melanoma cells in which GLI2 expression was reduced with shRNA were compared with mock-transduced cells for the development and progression of bone metastases. Bone metastases developed in 11 of the 12 (92%) mice inoculated with control shRNA-expressing 1205Lu cells, whereas only seven of the 12 (58%) mice that received the first population of shGLI2-expressing 1205Lu cells and four of the 13 (31%) mice that received the second population of shGLI2-expressing cells developed bone metastases (Figure 3, D). Osteolytic bone destruction, as measured by quantitative computerized image analysis on radiographs, was markedly less in mice inoculated with two distinct populations of shGLI2-expressing 1205Lu cells than in mice inoculated with control shRNA-transduced 1205Lu tumor cells (mean osteolytic tumor area for shCtrl vs shGLI2-1, 2.0 vs 0.73 mm², difference = −1.26 mm², 95% CI = −2.07 to −0.45, P < .001; mean for shCtrl vs shGLI2-2, 2.0 vs 0.49 mm², difference = −1.50 mm², 95% CI = −3.22 to −0.2, P = .042; mean for shGLI2-1 vs shGLI2-2, 0.73 vs 0.49 mm², difference = −0.24 mm², 95% CI = −1.99 to −1.5, P = .27) (Figure 3, E).

These experiments demonstrate that GLI2-high melanoma cells are more prone to form bone metastases than GLI2-low cell lines and that reduction of GLI2 levels in GLI2-high cells dramatically alters their ability to form bone metastases. Together, these data provide compelling evidence for a direct role for GLI2 in driving melanoma metastasis to bone.

**GLI2 Expression and Mesenchymal Transition in Melanoma Cells**

Changes in cell–cell adhesion molecules are associated with the acquisition of aggressive melanoma cell behavior (4,39,40). In normal skin, E-cadherin, encoded by the CDH1 gene, is expressed in melanocytes and keratinocytes and causes melanocytes to associate with keratinocytes. As melanoma progresses from its radial growth phase to a vertical growth phase, E-cadherin expression is lost and N-cadherin becomes expressed (4,39,40). N-cadherin, encoded by CDH2, allows melanocytes to interact with other N-cadherin–expressing cells, such as dermal fibroblasts and the vascular endothelium, thereby increasing their motility and invasiveness (4,39,40). In turn, these modifications of cell–cell interactions favor metastatic spreading of melanoma. Similar molecular changes occur during carcinoma progression in a cellular process often referred to as epithelial to mesenchymal transition (EMT) (41,42).

Among the transcription factors that are known to inhibit CDH1 expression during EMT are SNAIL and the closely related SLUG, as well as TWIST and SIP1 (42). Therefore, we examined the expression of these genes in our panel of melanoma cell lines by semi-quantitative RT-PCR. CDH1 expression was extremely variable (Figure 4, A). However, CDH1 expression levels were independent from those of SNAIL (eg, see lanes 7 and 8 vs 9 and 10). This disparity suggests that elevated SNAIL expression is not sufficient per se to drive the loss of CDH1 expression. Remarkably, none of the GLI2-high cell lines (Dauv1, WM852, WM793, or 1205Lu) expressed detectable levels of CDH1 mRNA (lanes 2, 6, 9, and 10). On the other hand, CDH1 mRNA was abundant in all GLI2-low cell lines (lanes 1, 3–5, 7, and 8) and in normal melanocytes (lane 11). CDH2 mRNA was expressed in all cell lines that expressed GLI2 at either high or intermediate levels (lanes 1, 2, and 5–10) and followed a pattern very similar to that of SNAIL mRNA. By contrast with SNAIL mRNA expression, steady-state levels of SLUG, TWIST, and SIP1 mRNA were roughly identical among all melanoma cell lines.

We also performed western blots on lysates from selected melanoma cell lines to determine whether protein expression would be similar to that of mRNA. Western analysis revealed that E-cadherin protein levels paralleled CDH1 mRNA levels in that only GLI2low cell lines had detectable E-cadherin protein expression (Figure 4, B).
GLI2 and CDH1 Expression in Human Cutaneous Melanoma In Vivo

We next examined GLI2 and CDH1 expression in three distinct sets of human melanoma samples. First, we performed in situ hybridization to localize areas with high GLI2 mRNA expression in a panel of 20 primary cutaneous melanoma lesions from the Department of Pathology in Nijmegen, the Netherlands. Parallel sections were immunostained for E-cadherin protein localization. We consistently observed heterogeneous expression of GLI2 and CDH1 in all tumor samples (representative examples in Figure 5, A, and in Supplementary Figure 1, available online). Specifically, in situ hybridization of a GLI2 riboprobe revealed strong GLI2 expression in the deep dermal compartment (Figure 5, A, panel e) but not in the superficial compartment (Figure 5, A, panel b) of the skin. In accordance with the expression pattern in melanoma cell lines (see Figure 4), tumor areas with low GLI2 expression were positive for presence of E-cadherin protein, as visualized by immunohistochemistry (Figure 5, A, panels c and d), whereas regions with elevated GLI2 mRNA were E-cadherin negative (Figure 5, A, panels f and g). High power magnification showed that E-cadherin protein expression was localized to the plasma membrane in GLI2-negative tumor cells (Figure 5, A, panel d).

Second, a panel of 17 cutaneous melanoma lymph node metastases from Hôpital Ambroise Paré in Boulogne-Billancourt, France, was screened for the expression of GLI2 and of CDH1 by multiplex semiquantitative RT-PCR. Of these 17 samples, two had notably higher levels of GLI2 mRNA (Figure 5, B, lanes 6 and 15, respectively), associated with low expression of CDH1 mRNA. All samples exhibited similar expression levels of the calcium-binding protein S100A6 gene, a specific marker of neural crest-derived cells that was used to demonstrate the presence of equivalent tumor material in all samples.

Third, GLI2 and CDH1 expression were determined in 42 randomly selected human melanoma samples from the UMDNJ Medical Center that represented four distinct stages of melanoma progression. The lowest levels of GLI2 expression were found in primary melanoma samples, and the highest levels were in distant metastases; however, these differences were not statistically significant (mean GLI2 expression in distant metastases vs primary tumors, 3.21 vs 1.18 relative units normalized against cyclophilin A (PPLA) expression, difference = −2.03, 95% CI = −5.29 to 1.23, P = .27) (Figure 5, C, left panel). Consistent with our findings in the melanoma cell lines, statistically significantly lower levels of CDH1 mRNA were detected in distant metastases as compared with primary tumors (CDH1 expression in distant metastases vs primary tumors, mean = 31.87 vs 123.6 relative units normalized against cyclophilin A; difference = 91.71, 95% CI = −8.89 to 192.3, P = .032) (Figure 5, C, center panel).

Discussion

In this report, we analyzed the specific role played by GLI2 in human melanoma. We demonstrated that GLI2 expression in melanoma cells is highly variable. High GLI2 expression was associated with an invasive and metastatic phenotype in vitro and in vivo and with mesenchymal traits, such as loss of E-cadherin expression and enhanced MMP secretion. Likewise, in human melanoma tumors, increased GLI2 expression was associated with loss of E-cadherin protein expression. Taken together, these data implicate GLI2 as an important modulator of melanoma progression and metastasis.

Over the past several years, major advances have been made in the identification of genetic and environmental factors that contribute to melanoma development. Defining biomarkers that are predictive of the risk of metastasis remains a major challenge. In this report, we demonstrate that GLI2 is a potent modulator of melanoma invasion and metastasis. Its expression is highly variable among human melanoma cell lines and tissue samples and is inversely correlated with the loss of E-cadherin protein expression. In functional studies, we unveil a direct role for GLI2 in driving melanoma cell invasiveness and metastasis. We previously identified GLI2 as a direct target of TGF-β signaling (23). Consistently, we found that high GLI2 expression in aggressive melanoma cell lines is driven, at least in part, by either autocrine or paracrine TGF-β signaling. Exogenous TGF-β is a potent inducer of GLI2 expression in a variety of cell types including melanoma cells (23), irrespective of their basal GLI2 expression status (data not shown). Incubation of the GLI2high cell lines 1205Lu and WM852 with the TGF-β receptor-I kinase inhibitor SB431542 resulted in a three- to fourfold reduction in steady-state levels of GLI2 mRNA (data not shown). We previously demonstrated that either systemic inhibition of TGF-β signaling with the small molecule TGF-β receptor-I inhibitor, SD-208, or overexpression of an inhibitory signaling component, SMAD7, can inhibit melanoma cell invasion in vitro and reduce the occurrence of experimental bone metastases in a mouse model (22,43). In the assays of bone metastasis in mice, both SD-208 and SMAD7 overexpression dramatically reduced GLI2 expression as retrospectively evaluated by real-time RT-PCR (data not shown). Likewise, in breast cancer cells, inhibition of TGF-β signaling also efficiently abrogated bone metastasis (33), whereas overexpression of GLI2 increased bone metastasis (44). Targeting GLI2 expression in melanoma cells by means of a specific shRNA dramatically reduced invasion of extracellular matrix in vitro (Figure 2) and experimental metastasis to bone in mice (Figure 3), two processes that are highly dependent on TGF-β signaling (21,22). Our findings thus provide new support for a critical role played by GLI2 downstream of TGF-β signaling to drive melanoma metastasis.

In epithelial cancers, loss of E-cadherin protein expression is a hallmark of EMT. This phenomenon is a complex phenotypic conversion that involves changes in morphology, differentiation markers, and cell–cell adhesion molecules, and acquisition of a motile behavior (42) that is functionally associated with poor prognosis in various cancers (41,45,46). Likewise, a mesenchymal transition is characteristic of melanoma switch from an early radial growth phase to vertical growth phase and subsequent metastasis (47,48). In this report, we determined that melanoma cell lines that exhibit high GLI2 at either the mRNA or the protein levels do not express E-cadherin. Reduction of GLI2 protein levels using shRNA provided evidence for a direct role for GLI2 in controlling melanoma invasion and metastasis to bone. We establish that high GLI2 expression in melanoma cell lines is associated with their metastatic potential and inversely correlated with loss of E-cadherin. Our expression data clearly indicate that loss of CDH1 expression is not necessarily associated with changes in SNAIL, SLUG, or TWIST expression, whereas it is consistently associated
with elevated steady-state levels of GLI2 mRNA (see Figure 4). Interestingly, the GLI1 protein, a direct GLI2 target (37), was shown to induce EMT in rat kidney epithelial cells via induction of the E-cadherin repressor, SNAIL (49). Future investigations will focus on the molecular events by which GLI2 controls the transition of melanoma cells to a mesenchymal phenotype.

Remarkably, opposite expression of GLI2 and CDH1 was also found in human melanoma samples. Using three independent sets of samples with distinct experimental approaches, we found that melanoma lesions express GLI2 and CDH1 at variable levels and that melanoma lesions are heterogeneous for GLI2 and E-cadherin expression and/or distribution. These findings are consistent with recent reports in the literature that have identified new regulators of melanoma progression, such as Brn2 or Dia-1, whose expression is also heterogeneous within tumors (50,51). E-cadherin plays a critical role in maintaining melanocyte interactions with epidermal keratinocytes and thus keeps progression to a metastatic state at bay. It is therefore reasonable to hypothesize that GLI2 may be a marker of melanoma aggressiveness; first, GLI2high melanoma cell lines are more invasive and metastatic than GLI2low cells, and second, high GLI2 expression in primary melanoma lesions was localized in the deeper part of the tumors and was consistent with a possible role for GLI2 in the progression toward an invasive phenotype. Larger cohorts of samples will be necessary to validate this observation.

Increased GLI2 expression was accompanied with statistically significant reduction of CDH1 expression in distant metastases as compared with primary melanoma tumors (Figure 5, C). In two sets of samples, we also examined whether more aggressive tumors expressed GLI2 at higher levels than less aggressive ones.
In making this assessment, we used clinical observations of time to metastasis and the extent of initial metastatic spread to define tumor aggressiveness. We found that the two most aggressive primary tumors and the two most aggressive distant metastatic lesions in this study expressed higher levels of GLI2 mRNA compared with their less aggressive counterparts. Inversely, in these two groups, the tumors that expressed the lowest levels of GLI2 mRNA were much more indolent.

This study has several limitations. First, we demonstrated a role for GLI2 in the metastatic activity of melanoma cells in vitro and in a mouse model of bone metastasis in which the experiments were conducted with immunocompromised mice. Immune function may affect the growth and dissemination of melanoma in human patients. In future investigations, it will be important to study whether GLI2 targeting interferes with melanoma metastasis in animal models with spontaneous metastasis. Second, we were not able to measure GLI2 protein levels in human tissue because of the lack of a suitable antibody when these studies were performed, and the number of human specimens that we analyzed was rather small. Newly released commercial antibodies are currently being tested for their specificity. Once adequate antibodies become available, immunohistochemical analyses will be performed on tissues from a larger cohort of patients, with sufficient sample size to allow us to determine whether there is a direct correlation between GLI2 protein expression and histopathological staging of human melanoma.

Taken together, our findings provide a strong rationale to further investigate the role of GLI2 in the initiation and progression of melanoma. Our future goals include the generation of genetic mouse models in which GLI2 function is altered specifically in the melanocyte lineage. It will also be very important to investigate whether GLI2 expression, or the GLI2 to CDH1 ratio, may be a marker of a more aggressive melanoma phenotype in a large cohort of human melanoma samples.

Supplementary Data

Supplementary data can be found at http://www.jnci.oxfordjournals.org/.

References


1158 Articles | JNCI Vol. 102, Issue 15 | August 4, 2010


